Biogen Idec Inc (BIIB) 420.04 $BIIB As Biogen P
Post# of 64068
Posted On: 03/16/2015 1:35:15 PM
Biogen Idec Inc (BIIB) 420.04 $BIIB
As Biogen Prepares to Reveal Alzheimer's Data, Expectations Are High
at The Street - 1 hr 19 mins ago
Biogen has added $25 billion in market value since the December -- a sign investors are willing to believe BIIB037 might succeed where several other similar Alzheimer's drugs have failed.
JNJ: 100.60 (+1.39), BIIB: 420.04 (+6.69), PFE: 34.45 (+0.45), LLY: 71.12 (+1.23)
Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF - Press Releases
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 8:30AM CDT
Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF
BIIB: 420.04 (+6.69), BBC: 33.77 (+0.32), BIB: 167.00 (+6.13), XBI: 230.57 (+2.14), AMGN: 162.00 (+7.74)
Adding A Few High Flyers To A Growth Portfolio
Abba's Aces - at Seeking Alpha - Sun Mar 15, 1:01PM CDT
NFLX: 418.85 (-19.55), BIIB: 420.04 (+6.69), FB: 77.55 (-0.50), RAD: 7.42 (-0.03)
Should Gilead Sciences Inc.’s Slowing Growth Concern Investors?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 15, 7:57AM CDT
The failure of the market to buy into Gilead Sciences ' amazing growth story is a flat-out mystery in the eyes of many investors. Despite growing product sales by an astounding 127% and non-GAAP earnings per share by 297% last year, the stock has...
BIIB: 420.04 (+6.69), ESRX: 83.55 (+2.18), GILD: 100.89 (+1.28), AMGN: 162.00 (+7.74), ABBV: 58.90 (+0.90), CELG: 120.26 (+2.53)
Stocks End Week On Down Note; Crude Oil Falls 9.6% For Week
at Investor's Business Daily - Fri Mar 13, 3:23PM CDT
Stocks ended firmly in the red Friday. On the plus side, buyers came in late and lifted major averages off session lows. The Dow Jones industrial average lost 0.8%, the S&P 500 gave up 0.6% and the Nasdaq eased 0.4%. Preliminary data showed NYSE and...
BIIB: 420.04 (+6.69), NXPI: 103.72 (-0.95), ULTA: 150.21 (+0.11), FLTX: 43.84 (-0.20)
3 Biotech ETFs Crushing the Market in 2015 - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Fri Mar 13, 11:02AM CDT
If you are looking for impressive biotech funds consider this trio, as all of its members have gained more than 20 percent so far this year.
BIIB: 420.04 (+6.69), BBC: 33.77 (+0.32), BIB: 167.00 (+6.13), XBI: 230.57 (+2.14), IBB: 351.95 (+6.62), AMGN: 162.00 (+7.74)
Cramer: Regeneron's Cholesterol Drug Is Going to Be Really Big
at The Street - Fri Mar 13, 10:27AM CDT
Forget about Biogen's Alzheimer's drug. TheStreet's Jim Cramer can't wait for data on fave Regeneron's cholesterol treatment this weekend.
BIIB: 420.04 (+6.69), REGN: 446.85 (+17.47)
Global Monoclonal Antibodies Pipeline Insight 2015
M2 - Thu Mar 12, 9:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pdplvw/global_monoclonal) has announced the addition of the "Global Monoclonal Antibodies Pipeline Insight 2015" report to their offering. Utility of mAbs in therapeutic treatment have been widely accepted among physicians and patients across the globe. This could be attributed to their high specificity due to which only diseased cells are eliminated while normal cells are spared. Their ability to bind target is high because they are made by using single antigen giving them high specificity. As a result, side effects are minimized as compared to other therapeutics available in global market. They are bit larger than other therapeutic molecules but they are highly customizable due to which they could be designed for particular disease. Clinical data has also shown that they have high safety and efficacy profiles due to which more patients are willing to include them in their regular therapeutic regime. They could be used to treat various ailments like cancer, auto-immune, anti-inflammatory and other disease indications. Out of these ailments, cancer mAb segment occupies major market shares and generates huge revenues across the globe. Pharmaceutical companies are trying to develop them for more ailments in other to generate diversify and strengthen their portfolio. Different mAbs have different action mechanism due to which they can be used against multiple malignancies. Depending upon malignancy in question, mAb could be customized due to which their dominance in global cancer market could be observed. For instance, rituximab is used for lymphoma treatment; it binds to the cancerous cells and makes it more susceptible to attack by immune system. On the other hand, Ibritumomab for Non-Hodgkin Lymphoma (NHL) treatment consists of radioactive pay load to eliminate cancerous cells. Chemotherapeutics are one of the major contenders having largest market shares in cancer category but their severe side effects noticeable during treatment. To alleviate patients' medical condition pharmaceutical companies have also launched the mAb version of chemotherapeutics. For instance, ado-trastuzumab emtansine has been launched in market for Her 2 positive breast cancer treatment. With existing product pipelines on the verge of being exhausted, it is most likely that the future years would witness an increased level of investments from the pharma companies so as to fill up their R&D pipelines. Additionally, a significant amount of research is being currently conducted to improve the level of potency of monoclonal antibodies. Cancer is becoming a major area where the use of monoclonal antibodies is increasing substantially in the recent years. In the future also, this field is expected to have the maximum application of mAbs. Global Monoclonal Antibodies Pipeline Insight 2015 Report Highlight: - Monoclonal Antibodies Classification - Mechanism of Monoclonal Antibodies - Global Monoclonal Antibodies Market Overview - Global Monoclonal Antibodies Clinical Pipeline by Company, Indication & Phase - Global Monoclonal Antibodies Clinical Pipeline: 1096 mAb - Marketed Monoclonal Antibodies: 66 mAb - Global Cancer Monoclonal Antibodies Clinical Pipeline: 602 mAb - Marketed Cancer Monoclonal Antibodies: 34 mAb Companies Mentioned - Abbvie - Amgen - Bayer HealthCare - Biogen Idec - Eli Lilly - Genmab - Gilead Sciences - GlaxoSmithKline - Novartis - Pfizer - Roche - Seattle Genetics For more information visit http://www.researchandmarkets.com/research/pd...monoclonal
BIIB: 420.04 (+6.69), GILD: 100.89 (+1.28), AMGN: 162.00 (+7.74), LLY: 71.12 (+1.23), GSK: 46.94 (+0.57), NVS: 98.00 (+0.96)
The Best Large Cap Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Thu Mar 12, 8:35AM CDT
OCR: 76.47 (+0.74), CAH: 89.74 (+1.62), SLG: 128.71 (+1.29), AET: 106.17 (+2.08), HSP: 87.64 (+0.08), VLO: 58.71 (+0.18), PNC: 95.74 (+0.05), HSIC: 139.75 (+3.38), HAS: 61.36 (+0.63), SWKS: 95.85 (+2.93), MCHP: 50.20 (+0.68), HRL: 55.25 (unch), NXPI: 103.72 (-0.95), BA: 153.21 (+1.64), COL: 94.55 (+1.32), COO: 188.69 (+2.85), NVDA: 22.83 (+0.13), LVLT: 54.46 (+0.05), AZO: 662.02 (+7.36), EQIX: 236.99 (+6.50), SIAL: 138.08 (+0.18), RJF: 59.00 (+0.28), FSL: 42.26 (-0.31), ASH: 126.59 (+1.59), BIIB: 420.04 (+6.69), BDX: 143.83 (+1.98), ACT: 304.24 (+5.29), CCK: 50.60 (+0.45), AON: 98.34 (+1.46), WSM: 82.38 (+0.23), CDW: 36.26 (+0.31), ADBE: 78.13 (+0.51), TSCO: 87.99 (+1.73), AGN: 241.05 (+3.71), DPS: 76.98 (+0.29), MDVN: 130.74 (+2.07), ANTM: 153.19 (+3.18), APH: 58.90 (+0.95), Q: 66.42 (+0.37), AGU: 112.21 (+1.79), FL: 61.22 (-0.09), XSD: 88.89 (+0.73), APD: 152.39 (+0.39), ABT: 47.72 (+0.84), CBG: 34.79 (+0.25), KR: 77.01 (+0.66), ORLY: 213.87 (+3.64), DIS: 107.50 (+1.06), GLW: 23.59 (+0.59), MAR: 83.16 (+1.08), DISH: 73.45 (-0.37), VRSN: 63.99 (+0.36), CTAS: 84.87 (+2.31), PLL: 101.75 (+2.14), SUNE: 23.95 (+0.29), TDG: 216.46 (+1.64), CMCSA: 59.34 (+0.29), CRM: 65.67 (+1.07)
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 1.47%
Comtex SmarTrend(R) - Wed Mar 11, 3:50PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $407.51 to a high of $416.24. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $409.61 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 420.04 (+6.69)
Biogen Idec Has Returned 24.7% Since SmarTrend Recommendation (BIIB)
Comtex SmarTrend(R) - Wed Mar 11, 9:25AM CDT
SmarTrend identified an Uptrend for Biogen Idec (NASDAQ:BIIB) on December 2nd, 2014 at $330.03. In approximately 3 months, Biogen Idec has returned 24.73% as of today's recent price of $411.66.
BIIB: 420.04 (+6.69)
Will Biogen Drug Score Big At Alzheimer's Conference?
at Investor's Business Daily - Wed Mar 11, 8:52AM CDT
A new research note from RBC Capital Markets offers a bullish take on Biogen Idec's (BIIB) experimental drug for Alzheimer's disease, predicting it will make a big splash at the upcoming International Conference on Alzheimer's and Parkinson's...
JNJ: 100.60 (+1.39), BIIB: 420.04 (+6.69), GILD: 100.89 (+1.28), PFE: 34.45 (+0.45), AMGN: 162.00 (+7.74), LLY: 71.12 (+1.23), CELG: 120.26 (+2.53)
Retinopathy Partnering Deals Analysis 2009-2014 (Updated 2014 Report)
M2 - Wed Mar 11, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrjwnh/retinopathy) has announced the addition of the "Retinopathy Partnering 2009-2014" report to their offering. Retinopathy Partnering 2009-2014 provides understanding and access to the retinopathy partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of retinopathy partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors retinopathy technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 20 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in retinopathy dealmaking in the biopharma industry since 2009 - Access to summary headline, upfront, milestone and royalty data - The leading retinopathy deals by value since 2009 In Retinopathy Partnering 2009-2014, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Companies Mentioned - Abbott - Actavis - Actelion - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Menarini - Merck & Co - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi - Servier - Shionogi For more information visit http://www.researchandmarkets.com/research/zr...etinopathy
JNJ: 100.60 (+1.39), BIIB: 420.04 (+6.69), NVO: 48.92 (+1.32), GILD: 100.89 (+1.28), BAX: 68.27 (+0.91), MRK: 57.08 (+0.88), LLY: 71.12 (+1.23), GSK: 46.94 (+0.57), BMY: 67.88 (+1.01), NVS: 98.00 (+0.96), CELGZ: 3.02 (-0.03)
Dry Eye Partnering Deals Analysis 2009-2014 (Updated 2014 Report)
M2 - Wed Mar 11, 6:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z6z9cn/dry_eye) has announced the addition of the "Dry Eye Partnering 2009-2014" report to their offering. Dry Eye Partnering 2009-2014 provides understanding and access to the dry eye partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of dry eye partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors dry eye technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 20 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in dry eye dealmaking in the biopharma industry since 2009 - Access to summary headline, upfront, milestone and royalty data - The leading dry eye deals by value since 2009 In Dry Eye Partnering 2009-2012, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Companies Mentioned - Abbott - Actavis - Actelion - Allergan - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Merck & Co - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Servier - Shionogi - Shire For more information visit http://www.researchandmarkets.com/research/z6z9cn/dry_eye
AGN: 241.10 (+3.76), JNJ: 100.60 (+1.39), BIIB: 420.04 (+6.69), NVO: 48.92 (+1.32), GILD: 100.89 (+1.28), BAX: 68.27 (+0.91), MRK: 57.08 (+0.88), LLY: 71.12 (+1.23), GSK: 46.94 (+0.57), BMY: 67.88 (+1.01), NVS: 98.00 (+0.96)
Be The 'Alpha Dog' With This Hedge Fund ETF
Nicholas Vardy - Seeking Alpha - Wed Mar 11, 5:35AM CDT
When it comes to leadership qualities, it helps to be an "alpha." The same applies in the world of investing. In the language of finance, "alpha" refers to the amount by which a portfolio outperforms its underlying index,...
BIIB: 420.04 (+6.69), BIDU: 205.13 (+0.68), ALFA: 44.76 (+0.33), GURU: 26.09 (+0.04), AAPL: 124.10 (+0.51)
Merck KGaA to Pay $3M to Opexa for Tcelna Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 10, 4:16PM CDT
Merck KGaA (MKGAF) announced an amendment to its agreement with Opexa for the development and marketing of Opexa's investigational compound, Tcelna.
LCI: 65.02 (-0.01), BIIB: 420.04 (+6.69), OPXA: 0.68 (+0.04), NVS: 98.00 (+0.96)
Biotechnology Boom
Young Money Monsters - at Seeking Alpha - Tue Mar 10, 4:48AM CDT
Editor's note: Originally published on March 6, 2015 by Jacob Urban Biotechnology has been the topic of many investment conversations of late, and as of now there might not be a hotter sector. Despite the rise in biotechnology over the past...
BBP: 31.84 (+0.27), PBE: 56.95 (+0.78), BIIB: 420.04 (+6.69), SBIO: 30.65 (+0.24), BBC: 33.77 (+0.32), GILD: 100.89 (+1.28), FBT: 123.38 (+2.51), XBI: 230.57 (+2.14), BBH: 133.25 (+2.94), AMGN: 162.00 (+7.74), CELG: 120.26 (+2.53)
How To Invest: Shire Shows Value Of High Closes
at Investor's Business Daily - Mon Mar 09, 4:39PM CDT
There are times when a company is so good or its products are so hot that you almost don't care what its chart looks like. But industries usually breed more than one good company. For the investor, a great base can be a differentiator. Take the Irish...
BIIB: 420.04 (+6.69), ACT: 304.27 (+5.32), SHPG: 245.73 (+1.55)
As Biogen Prepares to Reveal Alzheimer's Data, Expectations Are High
at The Street - 1 hr 19 mins ago
Biogen has added $25 billion in market value since the December -- a sign investors are willing to believe BIIB037 might succeed where several other similar Alzheimer's drugs have failed.
JNJ: 100.60 (+1.39), BIIB: 420.04 (+6.69), PFE: 34.45 (+0.45), LLY: 71.12 (+1.23)
Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF - Press Releases
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 8:30AM CDT
Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF
BIIB: 420.04 (+6.69), BBC: 33.77 (+0.32), BIB: 167.00 (+6.13), XBI: 230.57 (+2.14), AMGN: 162.00 (+7.74)
Adding A Few High Flyers To A Growth Portfolio
Abba's Aces - at Seeking Alpha - Sun Mar 15, 1:01PM CDT
NFLX: 418.85 (-19.55), BIIB: 420.04 (+6.69), FB: 77.55 (-0.50), RAD: 7.42 (-0.03)
Should Gilead Sciences Inc.’s Slowing Growth Concern Investors?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 15, 7:57AM CDT
The failure of the market to buy into Gilead Sciences ' amazing growth story is a flat-out mystery in the eyes of many investors. Despite growing product sales by an astounding 127% and non-GAAP earnings per share by 297% last year, the stock has...
BIIB: 420.04 (+6.69), ESRX: 83.55 (+2.18), GILD: 100.89 (+1.28), AMGN: 162.00 (+7.74), ABBV: 58.90 (+0.90), CELG: 120.26 (+2.53)
Stocks End Week On Down Note; Crude Oil Falls 9.6% For Week
at Investor's Business Daily - Fri Mar 13, 3:23PM CDT
Stocks ended firmly in the red Friday. On the plus side, buyers came in late and lifted major averages off session lows. The Dow Jones industrial average lost 0.8%, the S&P 500 gave up 0.6% and the Nasdaq eased 0.4%. Preliminary data showed NYSE and...
BIIB: 420.04 (+6.69), NXPI: 103.72 (-0.95), ULTA: 150.21 (+0.11), FLTX: 43.84 (-0.20)
3 Biotech ETFs Crushing the Market in 2015 - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Fri Mar 13, 11:02AM CDT
If you are looking for impressive biotech funds consider this trio, as all of its members have gained more than 20 percent so far this year.
BIIB: 420.04 (+6.69), BBC: 33.77 (+0.32), BIB: 167.00 (+6.13), XBI: 230.57 (+2.14), IBB: 351.95 (+6.62), AMGN: 162.00 (+7.74)
Cramer: Regeneron's Cholesterol Drug Is Going to Be Really Big
at The Street - Fri Mar 13, 10:27AM CDT
Forget about Biogen's Alzheimer's drug. TheStreet's Jim Cramer can't wait for data on fave Regeneron's cholesterol treatment this weekend.
BIIB: 420.04 (+6.69), REGN: 446.85 (+17.47)
Global Monoclonal Antibodies Pipeline Insight 2015
M2 - Thu Mar 12, 9:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pdplvw/global_monoclonal) has announced the addition of the "Global Monoclonal Antibodies Pipeline Insight 2015" report to their offering. Utility of mAbs in therapeutic treatment have been widely accepted among physicians and patients across the globe. This could be attributed to their high specificity due to which only diseased cells are eliminated while normal cells are spared. Their ability to bind target is high because they are made by using single antigen giving them high specificity. As a result, side effects are minimized as compared to other therapeutics available in global market. They are bit larger than other therapeutic molecules but they are highly customizable due to which they could be designed for particular disease. Clinical data has also shown that they have high safety and efficacy profiles due to which more patients are willing to include them in their regular therapeutic regime. They could be used to treat various ailments like cancer, auto-immune, anti-inflammatory and other disease indications. Out of these ailments, cancer mAb segment occupies major market shares and generates huge revenues across the globe. Pharmaceutical companies are trying to develop them for more ailments in other to generate diversify and strengthen their portfolio. Different mAbs have different action mechanism due to which they can be used against multiple malignancies. Depending upon malignancy in question, mAb could be customized due to which their dominance in global cancer market could be observed. For instance, rituximab is used for lymphoma treatment; it binds to the cancerous cells and makes it more susceptible to attack by immune system. On the other hand, Ibritumomab for Non-Hodgkin Lymphoma (NHL) treatment consists of radioactive pay load to eliminate cancerous cells. Chemotherapeutics are one of the major contenders having largest market shares in cancer category but their severe side effects noticeable during treatment. To alleviate patients' medical condition pharmaceutical companies have also launched the mAb version of chemotherapeutics. For instance, ado-trastuzumab emtansine has been launched in market for Her 2 positive breast cancer treatment. With existing product pipelines on the verge of being exhausted, it is most likely that the future years would witness an increased level of investments from the pharma companies so as to fill up their R&D pipelines. Additionally, a significant amount of research is being currently conducted to improve the level of potency of monoclonal antibodies. Cancer is becoming a major area where the use of monoclonal antibodies is increasing substantially in the recent years. In the future also, this field is expected to have the maximum application of mAbs. Global Monoclonal Antibodies Pipeline Insight 2015 Report Highlight: - Monoclonal Antibodies Classification - Mechanism of Monoclonal Antibodies - Global Monoclonal Antibodies Market Overview - Global Monoclonal Antibodies Clinical Pipeline by Company, Indication & Phase - Global Monoclonal Antibodies Clinical Pipeline: 1096 mAb - Marketed Monoclonal Antibodies: 66 mAb - Global Cancer Monoclonal Antibodies Clinical Pipeline: 602 mAb - Marketed Cancer Monoclonal Antibodies: 34 mAb Companies Mentioned - Abbvie - Amgen - Bayer HealthCare - Biogen Idec - Eli Lilly - Genmab - Gilead Sciences - GlaxoSmithKline - Novartis - Pfizer - Roche - Seattle Genetics For more information visit http://www.researchandmarkets.com/research/pd...monoclonal
BIIB: 420.04 (+6.69), GILD: 100.89 (+1.28), AMGN: 162.00 (+7.74), LLY: 71.12 (+1.23), GSK: 46.94 (+0.57), NVS: 98.00 (+0.96)
The Best Large Cap Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Thu Mar 12, 8:35AM CDT
OCR: 76.47 (+0.74), CAH: 89.74 (+1.62), SLG: 128.71 (+1.29), AET: 106.17 (+2.08), HSP: 87.64 (+0.08), VLO: 58.71 (+0.18), PNC: 95.74 (+0.05), HSIC: 139.75 (+3.38), HAS: 61.36 (+0.63), SWKS: 95.85 (+2.93), MCHP: 50.20 (+0.68), HRL: 55.25 (unch), NXPI: 103.72 (-0.95), BA: 153.21 (+1.64), COL: 94.55 (+1.32), COO: 188.69 (+2.85), NVDA: 22.83 (+0.13), LVLT: 54.46 (+0.05), AZO: 662.02 (+7.36), EQIX: 236.99 (+6.50), SIAL: 138.08 (+0.18), RJF: 59.00 (+0.28), FSL: 42.26 (-0.31), ASH: 126.59 (+1.59), BIIB: 420.04 (+6.69), BDX: 143.83 (+1.98), ACT: 304.24 (+5.29), CCK: 50.60 (+0.45), AON: 98.34 (+1.46), WSM: 82.38 (+0.23), CDW: 36.26 (+0.31), ADBE: 78.13 (+0.51), TSCO: 87.99 (+1.73), AGN: 241.05 (+3.71), DPS: 76.98 (+0.29), MDVN: 130.74 (+2.07), ANTM: 153.19 (+3.18), APH: 58.90 (+0.95), Q: 66.42 (+0.37), AGU: 112.21 (+1.79), FL: 61.22 (-0.09), XSD: 88.89 (+0.73), APD: 152.39 (+0.39), ABT: 47.72 (+0.84), CBG: 34.79 (+0.25), KR: 77.01 (+0.66), ORLY: 213.87 (+3.64), DIS: 107.50 (+1.06), GLW: 23.59 (+0.59), MAR: 83.16 (+1.08), DISH: 73.45 (-0.37), VRSN: 63.99 (+0.36), CTAS: 84.87 (+2.31), PLL: 101.75 (+2.14), SUNE: 23.95 (+0.29), TDG: 216.46 (+1.64), CMCSA: 59.34 (+0.29), CRM: 65.67 (+1.07)
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 1.47%
Comtex SmarTrend(R) - Wed Mar 11, 3:50PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $407.51 to a high of $416.24. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $409.61 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 420.04 (+6.69)
Biogen Idec Has Returned 24.7% Since SmarTrend Recommendation (BIIB)
Comtex SmarTrend(R) - Wed Mar 11, 9:25AM CDT
SmarTrend identified an Uptrend for Biogen Idec (NASDAQ:BIIB) on December 2nd, 2014 at $330.03. In approximately 3 months, Biogen Idec has returned 24.73% as of today's recent price of $411.66.
BIIB: 420.04 (+6.69)
Will Biogen Drug Score Big At Alzheimer's Conference?
at Investor's Business Daily - Wed Mar 11, 8:52AM CDT
A new research note from RBC Capital Markets offers a bullish take on Biogen Idec's (BIIB) experimental drug for Alzheimer's disease, predicting it will make a big splash at the upcoming International Conference on Alzheimer's and Parkinson's...
JNJ: 100.60 (+1.39), BIIB: 420.04 (+6.69), GILD: 100.89 (+1.28), PFE: 34.45 (+0.45), AMGN: 162.00 (+7.74), LLY: 71.12 (+1.23), CELG: 120.26 (+2.53)
Retinopathy Partnering Deals Analysis 2009-2014 (Updated 2014 Report)
M2 - Wed Mar 11, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrjwnh/retinopathy) has announced the addition of the "Retinopathy Partnering 2009-2014" report to their offering. Retinopathy Partnering 2009-2014 provides understanding and access to the retinopathy partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of retinopathy partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors retinopathy technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 20 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in retinopathy dealmaking in the biopharma industry since 2009 - Access to summary headline, upfront, milestone and royalty data - The leading retinopathy deals by value since 2009 In Retinopathy Partnering 2009-2014, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Companies Mentioned - Abbott - Actavis - Actelion - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Menarini - Merck & Co - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi - Servier - Shionogi For more information visit http://www.researchandmarkets.com/research/zr...etinopathy
JNJ: 100.60 (+1.39), BIIB: 420.04 (+6.69), NVO: 48.92 (+1.32), GILD: 100.89 (+1.28), BAX: 68.27 (+0.91), MRK: 57.08 (+0.88), LLY: 71.12 (+1.23), GSK: 46.94 (+0.57), BMY: 67.88 (+1.01), NVS: 98.00 (+0.96), CELGZ: 3.02 (-0.03)
Dry Eye Partnering Deals Analysis 2009-2014 (Updated 2014 Report)
M2 - Wed Mar 11, 6:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z6z9cn/dry_eye) has announced the addition of the "Dry Eye Partnering 2009-2014" report to their offering. Dry Eye Partnering 2009-2014 provides understanding and access to the dry eye partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of dry eye partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors dry eye technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 20 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in dry eye dealmaking in the biopharma industry since 2009 - Access to summary headline, upfront, milestone and royalty data - The leading dry eye deals by value since 2009 In Dry Eye Partnering 2009-2012, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Companies Mentioned - Abbott - Actavis - Actelion - Allergan - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Merck & Co - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Servier - Shionogi - Shire For more information visit http://www.researchandmarkets.com/research/z6z9cn/dry_eye
AGN: 241.10 (+3.76), JNJ: 100.60 (+1.39), BIIB: 420.04 (+6.69), NVO: 48.92 (+1.32), GILD: 100.89 (+1.28), BAX: 68.27 (+0.91), MRK: 57.08 (+0.88), LLY: 71.12 (+1.23), GSK: 46.94 (+0.57), BMY: 67.88 (+1.01), NVS: 98.00 (+0.96)
Be The 'Alpha Dog' With This Hedge Fund ETF
Nicholas Vardy - Seeking Alpha - Wed Mar 11, 5:35AM CDT
When it comes to leadership qualities, it helps to be an "alpha." The same applies in the world of investing. In the language of finance, "alpha" refers to the amount by which a portfolio outperforms its underlying index,...
BIIB: 420.04 (+6.69), BIDU: 205.13 (+0.68), ALFA: 44.76 (+0.33), GURU: 26.09 (+0.04), AAPL: 124.10 (+0.51)
Merck KGaA to Pay $3M to Opexa for Tcelna Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 10, 4:16PM CDT
Merck KGaA (MKGAF) announced an amendment to its agreement with Opexa for the development and marketing of Opexa's investigational compound, Tcelna.
LCI: 65.02 (-0.01), BIIB: 420.04 (+6.69), OPXA: 0.68 (+0.04), NVS: 98.00 (+0.96)
Biotechnology Boom
Young Money Monsters - at Seeking Alpha - Tue Mar 10, 4:48AM CDT
Editor's note: Originally published on March 6, 2015 by Jacob Urban Biotechnology has been the topic of many investment conversations of late, and as of now there might not be a hotter sector. Despite the rise in biotechnology over the past...
BBP: 31.84 (+0.27), PBE: 56.95 (+0.78), BIIB: 420.04 (+6.69), SBIO: 30.65 (+0.24), BBC: 33.77 (+0.32), GILD: 100.89 (+1.28), FBT: 123.38 (+2.51), XBI: 230.57 (+2.14), BBH: 133.25 (+2.94), AMGN: 162.00 (+7.74), CELG: 120.26 (+2.53)
How To Invest: Shire Shows Value Of High Closes
at Investor's Business Daily - Mon Mar 09, 4:39PM CDT
There are times when a company is so good or its products are so hot that you almost don't care what its chart looks like. But industries usually breed more than one good company. For the investor, a great base can be a differentiator. Take the Irish...
BIIB: 420.04 (+6.69), ACT: 304.27 (+5.32), SHPG: 245.73 (+1.55)
(0)
(0)